GE HealthCare Technologies Inc. (GEHC) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Sell if holding. Momentum 1.9/10 is below the 5.0 floor at $60.12 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (2); Concentration risk — Geographic: outside the U.S..
GE HealthCare provides medical technology, pharmaceutical diagnostics, and AI/software solutions through four segments—Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics—serving customers in 160+ countries with approximately 54,000... Read more
Sell if holding. Momentum 1.9/10 is below the 5.0 floor at $60.12 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (2); Concentration risk — Geographic: outside the U.S.. Chart setup: Death cross, below all MAs, RSI 22, MACD bearish. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicoutside the U.S.10-K Item 1A: 'We generate the majority of our revenue outside of the U.S.'
- MEDIUMGeographicChina10-K Item 1A: 'China has implemented volume-based procurement processes to constrain healthcare costs'
Material Events(8-K, last 90d)
- 2026-03-17Item 5.02LOWKevin A. Lobo appointed to Board and Talent, Culture, and Compensation Committee effective March 13, 2026. Non-executive director appointment; no arrangement cited.SEC filing →
- 2026-02-27Item 1.01MEDIUMOn February 26, 2026, GE HealthCare entered into a $0.5 billion 364-Day Revolving Credit Agreement with JPMorgan Chase, maturing February 25, 2027. Replaces the 2025 364-day facility terminated same day.SEC filing →
- 2026-02-27Item 1.02MEDIUMPrior $0.5 billion 364-Day Revolving Credit Agreement dated March 27, 2025 terminated on February 26, 2026 upon entry into new revolving credit facility with JPMorgan Chase. No default cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.9/10 is below the 5.0 floor at $60.12 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (2); Concentration risk — Geographic: outside the U.S.. Chart setup: Death cross, below all MAs, RSI 22, MACD bearish. Prior stop was $56.99. Score 5.1/10, moderate confidence.
Take-profit target: $80.76 (+34.2% upside). Prior stop was $56.99. Stop-loss: $56.99.
Concentration risk — Geographic: outside the U.S.; Consecutive earnings misses (2); Weak growth.
GE HealthCare Technologies Inc. trades at a P/E of 14.3 (forward 10.7). TrendMatrix value score: 7.8/10. Verdict: Sell.
28 analysts cover GEHC with a consensus score of 3.9/5. Average price target: $90.
What does GE HealthCare Technologies Inc. do?GE HealthCare provides medical technology, pharmaceutical diagnostics, and AI/software solutions through four...
GE HealthCare provides medical technology, pharmaceutical diagnostics, and AI/software solutions through four segments—Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics—serving customers in 160+ countries with approximately 54,000 employees. The majority of revenue is generated outside the U.S. from hospitals, health systems, and researchers.